Neuroscience
From the FDA:
FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri
For Immediate Release: January 20, 2012
[snip]
Read the full press release
- Fda: Updated Info On Tysabri (natalizumab)
From the FDA: Information on Natalizumab (marketed as Tysabri) Updated Information: [9/2009] The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri. Tysabri was approved by the FDA for the...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the FDA: FOR IMMEDIATE RELEASE P06-25 February 16, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Allows Clinical Studies of Tysabri (natalizumab) for Treatment of MS to Proceed The Food and...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Post Tysabri (natalizumab): What Choices In M.s. Treatment?
The Consumer: Exploring Choices for M.S. By MARY DUENWALD The New York Times 15 March 2005 [snip] An estimated 5,000 patients who had been taking Tysabri since the Food and Drug Administration approved it in late November are now advised to see their...
- Tysabri (natalizumab) Suspension
FOR IMMEDIATE RELEASE P05-07 February 28, 2005 Media Inquiries: 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Issues Public Health Advisory on Tysabri, a New Drug for MS The Food and Drug Administration (FDA) today issued a public health advisory...
Neuroscience
FDA: progressive multifocal leukoencephalopathy (PML) and Tysabri (natalizumab)
From the FDA:
FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri
For Immediate Release: January 20, 2012
[snip]
"Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn’s disease (CD).[snip]
"The Stratify JCV Antibody ELISA test, when used with other clinical data from the patient, can help health care providers determine the risk for developing PML in MS and CD patients."
Read the full press release
- Fda: Updated Info On Tysabri (natalizumab)
From the FDA: Information on Natalizumab (marketed as Tysabri) Updated Information: [9/2009] The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri. Tysabri was approved by the FDA for the...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the FDA: FOR IMMEDIATE RELEASE P06-25 February 16, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Allows Clinical Studies of Tysabri (natalizumab) for Treatment of MS to Proceed The Food and...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Post Tysabri (natalizumab): What Choices In M.s. Treatment?
The Consumer: Exploring Choices for M.S. By MARY DUENWALD The New York Times 15 March 2005 [snip] An estimated 5,000 patients who had been taking Tysabri since the Food and Drug Administration approved it in late November are now advised to see their...
- Tysabri (natalizumab) Suspension
FOR IMMEDIATE RELEASE P05-07 February 28, 2005 Media Inquiries: 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Issues Public Health Advisory on Tysabri, a New Drug for MS The Food and Drug Administration (FDA) today issued a public health advisory...